CAR-T cells targeting CD20 and CD30 for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 to 69 years old.
- Your lymphoma has come back or not responded to at least two prior treatments, including a stem cell transplant if you had one.
- Your lymphoma cells have CD20, CD30, or both proteins on their surface.
- You have one of these types: diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, transformed follicular lymphoma, mantle cell lymphoma, high-grade B-cell lymphoma, CLL/SLL, or Hodgkin lymphoma.
- You are well enough to have a blood draw for the treatment (adequate vein access) and have not had certain other cancer treatments recently.
- You are not pregnant and are willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
This trial tests a new type of CAR-T cell therapy that targets both CD20 and CD30 proteins on lymphoma cells. It is for people whose lymphoma has returned or not responded after multiple treatments, including stem cell transplant.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
Hear when a new Relapsed/Refractory Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.